Sentinel node biopsy for breast cancer

Sentinel node biopsy is more frequently being used as a replacement for axillary node dissection as single and multicenter trials confirm its ability to predict the presence of disease in the remaining lymph nodes. There have been a variety of techniques used with varying success and data supporting each of these techniques is presented. In addition, a number of factors have been found to influence the identification and false negative rates, and these are discussed as well. There remain many areas of controversy surrounding this new surgical technique, including: the appropriate method of pathological analysis of the sentinel node, use of lymphoscintigraphy, usefulness of internal mammary sentinel node biopsy, and use of sentinel node biopsy for ductal carcinoma in situ. The Literature is reviewed on these controversial areas.     

Sentinel node biopsy in breast cancer

Axillary lymph node dissection (ALND) is an important tool in staging patients with breast cancer. However, this procedure has several sequelae and complications and improvement in early diagnosis has led to an increasing number of cases of ALND in which axillary nodes are found to be negative. Sentinel node (SN) biopsy appears to be a less invasive alternative to ALND. The aim of the present study was to assess whether SN is a reliable indicator for axillary staging. We studied 126 consecutive patients with T1-T2 breast cancer and clinically negative axilla. In each case, 30-70 MBq of 99mTC-labelled colloidal albumin was injected subdermally close to the tumour and SN was visualised by lymphoscintigraphy. Surgery was performed 24 h after injection and the SN was removed under the guidance of a gamma ray-detecting probe. ALND was then undertaken in all cases. A histopathologic examination of the SNs was then made and the findings compared with the status of the other axillary nodes. SNs were identified and biopsied in 115/126 patients (91.3%) and correctly predicted the axillary status in 110/115 cases (95.6%). In five cases (4.4%), SNs were found to be negative, but other axillary nodes were positive. Our data confirm that SN biopsy is a good method for staging the axilla in patients with breast cancer. However, before SN biopsy can replace ALND in daily clinical practice, some technical aspects must be standardized, and clinical trials are required in order to clarify the prognostic impact of false-negative cases.     

Sentinel node biopsy in breast cancer

Background: Sentinel lymph node biopsy (SNB) in breast cancer may be used in place of axillary lymph node dissection (ALND) if SNB accurately stages the axilla. This study assessed the success and accuracy of axillary SNB with isosulfan blue (ISB) and technetium-99 sulfur colloid (TSC) compared to ALND. Methods: Forty-two women with T1 or T2 breast cancer underwent SNB and ALND. Sixty to 90 minutes before anesthetic induction, a mixture of 3 mL ISB and 1 mCi TSC was injected around the primary cancer or prior biopsy site. Intraoperatively, the SLN was identified using a gamma detector (Neoprobe 1000) or by visualization of the blue-stained lymph node and afferent lymphatics. The SLN was excised separately, and a level I/II ALND was completed. The histologic findings of the axillary contents and SLN were compared. Results: An axillary SLN was found in 38 of 42 (90%) cases. SLN localization rate and predictive value were the same for women who had and those who had not undergone excisional biopsy before the date of SNB. Fifteen of 42 (36%) patients had lymph node metastases. The SLN was positive in all women with axillary metastases (negative predictive value, 100%). Conclusions: If confirmed by larger series, a negative SNB may eliminate the need for ALND for select women with breast cancer. Presented at the 50th Annual Cancer Symposium of The Society of Surgical Oncology, Chicago, Illinois, March 20–23, 1997.     

乳腺癌哨兵淋巴结活检

近三十年来,乳腺癌的发病率呈明显上升的趋势。在美国,2001年新诊断病例为139700,死亡病例为40600,2002年新诊断病例为205000,死亡病例为40000。乳腺癌已成为美国妇女最常见的恶性肿瘤,其癌症死亡率仅次于肺癌。在我国,根据1997年的统计资料,北京、天津、上海地区不同年龄女性乳腺癌世界人口标化发病率分别为27.8/10万,30.1/10万,25.5/10万,同美国西欧相似,呈明显上升的趋势。发病率上升的同时,乳腺癌手术范围的变化也经历了一系列重要的历程:从19世纪末经     

Preoperative radiotherapy for rectal cancer: implications for surgeons, pathologists and radiologists

BACKGROUND: Over 10,000 new cases of rectal cancer are reported in the UK each year and adjuvant treatments, such as preoperative radiotherapy, are now being used almost routinely. METHODS: A literature review was performed on the Medline database for English language publications on preoperative radiotherapy and rectal cancer. The radioresponsiveness of rectal cancer, tumour downstaging, radiological staging of irradiated rectal cancer, effects of radiotherapy on anastomotic integrity, anorectal and genitourinary function, the role of preoperative radiotherapy in local excision of rectal cancer, and the histological changes peculiar to radiotherapy were evaluated. Results and conclusion: Following preoperative radiotherapy, rectal cancer may be downstaged or, occasionally, eradicated histologically. Rectal cancer can now be staged accurately before operation, but this is significantly less reliable following irradiation. The pathological specimen must be examined thoroughly before a tumour can be reported to have been eradicated, especially as unique histological changes are produced by radiotherapy. There is no evidence to suggest that preoperative radiotherapy adversely affects anastomotic integrity. It appears that preoperative radiotherapy has some adverse affects on long-term anorectal dysfunction, but this must not distract from its main objectives in rectal cancer, namely reduced local recurrence rates and improved overall survival.     

Sentinel node biopsy in breast cancer revisited

The axilla has long been a focus of clinicians' attention in the management of breast cancer. The approach to the axilla has undergone dramatic changes over the last century, from radical and extended radical excisions, through the introduction of sentinel node biopsy for node negative patients to the current situation where selective management of those with nodal involvement is being introduced.The introduction of lymphatic mapping and sentinel node biopsy in the 1990's has been key to the major changes that have occurred. In less than 20 years it has moved from a hypothesis to a situation where it is the default approach to almost all clinically node negative patients and is being considered in other situations where axillary clearance was previously considered standard. This article reviews the development and introduction of sentinel node biopsy, its current uncertainties and limitations, and possible future developments.     

Sentinel lymph node biopsy in breast cancer

One of the most important prognostic indicators in patients with breast cancer is axillary lymph node status. Sentinel lymph node (SLN) biopsy has emerged as a potential alternative to routine axillary dissection in clinically node-negative early breast cancer. This procedure requires a specialized but multidisciplinary approach utilizing the surgeon, nuclear radiologist and pathologist. SLN biopsy allows adequate assessment of the axillary nodal status in patients with early breast cancer, with minimal-if any-morbidity. Blue dye and lymphoscintigraphy are complementary techniques, and the success rate is maximized when the two methods are used together. Focused histopathologic examination on one or two lymph nodes most likely to contain metastases [SLN(s)], using serial sectioning and immunohistochemical techniques, allows an improved staging to be performed. Detection of metastases on SLN(s) is not only a prognostic indicator, but it also dictates whether the patient should receive further surgery and adjuvant chemotherapy. Until data regarding the long-term results of the SLN biopsy are available, this method should be considered investigational and be performed by surgeons experienced in this technique to achieve a failure rate of less than 2 per cent.     

Sentinel lymph node biopsy and breast cancer

BACKGROUND AND METHOD: This paper reviews and discusses the feasibility and accuracy of sentinel lymph node (SLN) biopsy in breast cancer. A standardized method of identifying the SLN and detecting micrometastases is suggested, along with a strategy for the elimination of routine axillary lymph node dissection (ALND). RESULTS: Although the SLN can be identified successfully by experienced practitioners using either the dye-guided or gamma probe-guided method, identification is facilitated when the two techniques are combined. To improve the likelihood of spotting metastases in the SLN, it is desirable to perform step sectioning combined with haematoxylin and eosin staining and immunohistochemistry of permanent and frozen sections. SLN biopsy is as accurate for T2 tumours as it is for T1 tumours. However, it is highly unlikely that all false-negative cases can be eliminated, even by detailed histological examination. Nevertheless, patients with T1 tumours with micrometastases in the SLN have shown no evidence of tumour in the non-sentinel nodes. In other words, ALND can be avoided in these patients, even if histological examination of the SLN fails to detect micrometastasis. CONCLUSION: In practice, routine ALND can be avoided in patients with T1 tumours when the identified SLN proves to be histologically negative. However, investigation of long-term regional controls and of survival in a prospective randomized trial is necessary before SLN biopsy can replace routine ALND, particularly for patients with T2 tumours.     

乳腺癌前哨淋巴结活检

目的 评价前哨淋巴结活检预测腋窝淋巴结有无肿瘤转移的准确性及其临床意义。方法 用^99m锝－硫胶体作为示踪剂,用γ探测仪导向,对70例临床分期为T1－2N0M0的乳腺癌患者进行前哨淋巴结活检,所有的患者均同时行腋窝淋巴结清扫,HE染色阴性的前哨淋巴结再切片,用CK8、CK19、KP－1行免疫组织化学染色。结果 70例患者中成功发现前哨淋巴结的有67例,发现率为95.7%（67／70）。前哨淋巴结的数量为1－5枚,平均每例1.6枚。非前哨淋巴结5－20枚,平均例12.3枚。67例前哨淋巴结活检成功的患者中,29例患者（43.3%）有腋窝淋巴结转移,其中前哨淋巴结有转移者24例（35.8%）,前哨淋巴结未发现转移而非前哨淋巴结有转移者5例（7.5%）。7例患者（10.4%）只有有淋巴结为阳性淋巴结,前哨淋巴结活检的准确性为100％。43例患者的65枚HE染色阴性一的前哨淋巴结,CK8及CK19免疫组织化学染色均为阴性。结论 前哨淋巴结检能较准确地预测腋窝淋巴结转移情况,对原发灶为T1的乳腺癌,前哨淋巴结活检的准确性为100％。同一层面切片行免疫组织化学染色并不能提高淋巴结微转移癌的发现率。     

前哨淋巴结活检与乳腺癌

前哨淋巴结 (ｓｅｎｔｉｎｅｌｌｙｍｐｈｎｏｄｅ ,ＳＬＮ)是指某器官某区域组织的淋巴液首先引流到一个或几个少数的特定区域淋巴结。理论上 ,ＳＬＮ无转移 ,则该器官该区域发生的恶性肿瘤转移到另外的淋巴结的可能性很小。这个概念是Ｃａｂａｎａｓ于 1977年在阴茎癌的研究中最早提出的。前哨淋巴结的概念只有引入到经淋巴途径转移的肿瘤中才是合理的。腋窝淋巴结解剖是乳腺癌手术的常规术式 ,然而术后上肢淋巴水肿是目前国内外临床治疗上的一大难题。Ｋｒａｇ等[1] 开展了乳腺癌的前哨淋巴结活检 (ｓｅｎｔｉｎｅｌｌｙｍｐｈｎｏｄｅｂ…     

Sentinel node biopsy for breast cancer: a critical analysis

The concept of sentinel node biopsy, initially introduced for melanoma, has also been used for breast cancer since the 90's, in that, with the increasingly, widespread use of mammographic screening and of other minimally invasive diagnostic procedures, smaller and smaller cancers are now being diagnosed. For these cancers axillary dissection often constitutes overtreatment. For cancers at an initial stage with a low risk of axillary metastases investigation of sentinel lymph nodes enables us the surgeon to assess the axillary lymph-node status and avoid axillary dissection which is responsible for a certain amount of morbidity. Sentinel nodes can be sought using colorimetric or radioisotope methods. To date there is no common consensus of opinion as to which is the better procedure and the respective indications. Both methods allow detection of sentinel nodes in roughly 90% of cases and the combination of the two yields 100% detection rates. It is widely accepted that sentinel node biopsy should be reserved for unifocal tumours which have not been treated previously and which measure less than 15 mm in diameter. The advantages of the procedure are substantial provided it is performed correctly by surgeons properly trained in its use. The learning curve is relatively brief and is based on no more than 30-40 cases.